Herve A. Loiseau
Toulouse, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020.
Journal: Cancer medicine
Published: October 04, 2024
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
Journal: British journal of haematology
Published: November 20, 2022
All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study.
Journal: Haematologica
Published: December 06, 2021
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
Journal: Nature communications
Published: October 16, 2020
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Journal: Blood
Published: July 14, 2018
DKK1 and sclerostin are early markers of relapse in multiple myeloma.
Journal: Bone
Published: June 26, 2017
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.
Journal: Journal of Cancer
Published: January 10, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026